Blue Bell, Pennsylvania (BUSINESS WIRE) — Mitochon Pharmaceuticals today announced that it was awarded Orphan Drug Designation by FDA for its mitochondrial targeted compound, MP-101 for treating Huntington’s Disease. This important allowance, along with the Company’s open IND will help secure the path forward for the continued clinical development of MP101 in Huntington…(Read More)

Disease Modifying Therapies for Neurodegenerative Diseases…(Read More)

Blue Bell, Pennsylvania (BUSINESS WIRE) — Mitochon Pharmaceuticals today announced that it was notified by the US Patent and Trade Mark Office of allowance on its first patent, US 15/002,531 “INDUCED EXPRESSION OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) FOR TREATMENT OF NEUROMUSCULAR, NEURODEGENERATIVE, AUTOIMMUNE, DEVELOPMENTAL AND/OR METABOLIC DISEASE”. This patent allowance will help…(Read More)

Blue Bell, Pennsylvania (BUSINESS WIRE)–Mitochon Pharmaceuticals today announced that it was awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to help develop its mitochondrial targeted compounds for treating Parkinson’s disease. The funding will go to pivotal animal studies to assess the benefits of Mitochon’s compounds in…(Read More)

Optic neuritis is an inflammatory demyelinating disease of the optic nerve often associated with multiple sclerosis (MS) [1]. Optic neuritis may lead to complete or partial loss of vision in one or both eyes [2]. In 15%–20% of people who eventually develop MS, optic neuritis is their first symptom [3]. Current therapies used for…(Read More)

Huntington’s disease (HD) is a neurodegenerative disorder caused by a CAG repeat expansion in the first exon of the gene huntingtin. There is no treatment to prevent or delay the disease course of HDcurrently. Oxidative stress and mitochondrial dysfunction have emerged as key determinants of the disease progression in HD. Therefore, counteracting mutant huntingtin…(Read More)

Recent findings have elucidated roles for mitochondrial uncoupling proteins (UCPs) in neuronal plasticity and resistance tometabolic and oxidative stress. UCPs are induced by bioenergetic challenges such as caloric restriction and exercise and may protect neurons against dysfunction and degeneration. The pharmacological uncoupler 2,4-dinitrophenol (DNP), which was once prescribed to >100,000 people as…(Read More)

Mitochon’s mission is to bring forward meaningful drugs that work at the root of insidious neurological diseases. By harnessing the power of the mitochondria, they believe that devastating diseases like Huntingtons disease, Duchennes muscular dystrophy and multiple sclerosis can be hastened and lives can be more fully lived…(Read More)

The First Mitochondrial Targeted Agent to Treat Neurodegenerative Diseases Blue Bell, Pennsylvania (BUSINESS WIRE) — Mitochon Pharmaceuticals today announced completion of its second year of funding with a total investment of $1.6 million. The proceeds from the financing will be used to advance Mitochon’s lead compound MP101, a first in class mitochondrial targeted neuro…(Read More)